Evolving Considerations in the Management of Chronic Lymphocytic Leukemia (CLL): Optimizing Clinical and Economic Outcomes with BTK Inhibitors

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2023, to March 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AbbVie, AstraZeneca and Merck Sharpe & Dohme LLC

Description:
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. CLL is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In 2022, it is expected that there will be 20,160 new cases of CLL and about 4,410 deaths, which represents an increase in both numbers. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Fortunately for patients with CLL, several new treatments have recently become available giving clinicians many new options to improve patient outcomes with these new treatments and strategies. New combination regimens have recently become available that have shown the ability to greatly improve outcomes in previously untreated CLL. This activity focuses on these evolving options, outlines how to incorporate quality measures for the diagnosis and management of CLL, and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of chronic lymphocytic leukemia (CLL), including factors that contribute to poor prognosis and increased costs

  • Discuss the molecular pathophysiology associated with the development of CLL, the role of the B-cell receptor (BCR) pathway, and the rationale for therapeutically targeting this pathway

  • Compare and contrast recent safety and efficacy data on BTK inhibitors, and especially their combinations, in CLL

  • Evaluate the latest clinical CLL guideline recommendations for selection and sequencing of therapy, individualized to the patient, including mutation status, performance status, comorbidities, and patient preferences

  • Differentiate the safety profiles for BTK inhibitors and their combinations as well as monitoring and management strategies to mitigate adverse effects

  • Analyze the cost drivers associated with the management of CLL and the value of evolving treatment approaches in lowering cost of care and healthcare utilization

     

Faculty: John N. Allan, MD
Assistant Professor of Medicine
Weill Cornell Medicine

Disclosure:

(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Allan has served as a consultant for Abbvie, AstraZeneca, Beigene, Epizyme, Genentech, JanssAbbvie, AstraZeneca, Beigene, Epizyme, Genentech, Janssen, Pharmacyclics, and TG Therapeutics. He has served on the speaker's bureau for Abbvie, AstraZeneca, BeiGene, JAbbvie, AstraZeneca, BeiGene, Janssen, and Pharmacyclics. He has received grant/research support from BeiGene, Celgene, Genentech, Janssen, and TG Therapeutics. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AbbVie, AstraZeneca and Merck Sharpe & Dohme LLC


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue